MOTS-c vs SS-31: Mitochondrial Peptides Compared

Summary

MOTS-c and SS-31 both relate to mitochondrial function but sit at very different stages. MOTS-c is an endogenous mitochondrial-derived peptide acting as a metabolic signal; SS-31 (elamipretide) is a synthetic cardiolipin-binding compound that has completed multiple human clinical trials, with mixed primary endpoint results.

Last reviewed 2026-09-01

What it is

MOTS-c is a 16–amino-acid peptide encoded within the mitochondrial 12S rRNA gene. SS-31, also called elamipretide, is a synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane.

MOTS-c was identified in 2015 as part of the emerging mitochondrial-derived peptide field. SS-31 came out of Szeto and Schiller's work on mitochondria-targeted peptides and progressed through clinical development as elamipretide for primary mitochondrial myopathy and Barth syndrome.

MOTS-c is endogenous and mitochondrially encoded; SS-31 is fully synthetic.

The pair illustrates the difference between a signalling molecule still in early research and a structurally targeted compound that has actually been tested in patients.

How it works

In plain terms

MOTS-c is a message the mitochondria send to the rest of the cell about energy status. SS-31 does something more physical — it binds to a specific fat in the mitochondrial membrane and helps the energy machinery hold its shape.

Technical detail

MOTS-c translocates to the nucleus under metabolic stress and regulates nuclear gene expression, and has been reported to activate AMPK and interfere with the folate–methionine cycle, reducing purine biosynthesis. SS-31 binds cardiolipin, a phospholipid unique to the inner mitochondrial membrane essential for cristae architecture and respiratory supercomplex assembly. By stabilising cardiolipin interactions, SS-31 improves electron transport efficiency and reduces electron leak, lowering reactive oxygen species production at source rather than scavenging it.

Pathways involved

MOTS-c: AMPK activation, nuclear translocation, folate–methionine cycle
SS-31: cardiolipin binding, cristae stabilisation, supercomplex assembly
Both: downstream effects on mitochondrial respiration efficiency

Current research

Laboratory research

Both mechanisms are supported by cell and isolated mitochondria work; SS-31's cardiolipin interaction is structurally characterised.

Animal research

MOTS-c improved insulin sensitivity and exercise capacity in aged mice and reduced diet-induced obesity in rodent models. SS-31 improved mitochondrial function across cardiac, renal and skeletal muscle injury models.

Human research

MOTS-c has human observational work — circulating levels decline with age and vary with exercise — but no controlled interventional trial. SS-31 as elamipretide has completed multiple clinical trials including MMPOWER-3 in primary mitochondrial myopathy, which missed its primary endpoints, and Barth syndrome work with more encouraging signals. That gap in clinical stage is the most important difference between them.

Ongoing research

Elamipretide development continues in specific mitochondrial disease indications; MOTS-c remains preclinical.

What is being investigated

Metabolic signalling and insulin sensitivity (MOTS-c)
Exercise capacity and mitochondrial adaptation
Cristae architecture and respiratory efficiency (SS-31)
Primary mitochondrial myopathy and Barth syndrome (elamipretide)

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

MOTS-c has no controlled human interventional data at all
SS-31's largest myopathy trial missed its primary endpoints, which tempers the mechanism's clinical promise
Mitochondrial biomarkers improving does not reliably translate to functional benefit
Neither compound is approved for general use
Age-related decline in a circulating peptide does not establish that restoring it helps

Evidence ratings

Laboratory studies

Moderate

Both mechanisms supported; SS-31 structurally characterised.

Animal studies

Moderate

Consistent metabolic and mitochondrial findings for both.

MOTS-c human data

Limited

Observational only; no interventional trials.

SS-31 human data

Moderate

Multiple trials completed, mixed primary endpoint results.

Comparisons

BPC-157 vs TB-500

The equivalent comparison in repair peptides.

References

[1]MOTS-c identification and metabolic role — PubMed / Cell Metabolism, 2015
[2]SS-31 / elamipretide cardiolipin mechanism — PubMed, 2013–present
[3]MMPOWER-3 elamipretide trial — PubMed / ClinicalTrials.gov, 2021
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is MOTS-c?+

A 16–amino-acid mitochondrial-derived peptide encoded in the 12S rRNA gene, acting as a metabolic stress signal.

What is SS-31?+

A synthetic tetrapeptide, also called elamipretide, that binds cardiolipin in the inner mitochondrial membrane.

Which is further along in humans?+

SS-31 by a wide margin — it has completed multiple clinical trials, while MOTS-c has only observational human data.

Did elamipretide trials succeed?+

MMPOWER-3 in primary mitochondrial myopathy missed its primary endpoints; Barth syndrome work produced more encouraging signals.

Why does cardiolipin matter?+

It is essential for cristae architecture and respiratory supercomplex assembly, so stabilising it improves electron transport efficiency.

Does MOTS-c decline with age?+

Circulating levels have been reported to decline with age, but that observation does not establish benefit from restoring them.

Are they antioxidants?+

Not conventionally. SS-31 reduces reactive oxygen species production at source rather than scavenging existing radicals.

Can they be compared directly?+

Not usefully on efficacy — they target different problems and sit at completely different stages of evidence.

Continue your research

MOTS-c research

SS-31 research

Mitochondrial function